Lead sponsor
Qilu Pharmaceutical Co., Ltd.
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
2
Trials led
1
Ongoing
956
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 3
2
Trials by status
Not yet recruiting
1
Unknown
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 DiabetesBMI 18.5-35Ph 3Unknown478
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 DiabetesBMI ≥22Ph 3Not yet recruiting478